Key facts
- It has raised $10.0M; the latest was Seed Round ($10.0M) in Jan 2026.
- Notable investors include K2VC, Shanghai Healthcare Capital, Elikon Venture, Everjoy Fortune, Taihill Venture.
- Status: Privately Held (backing).
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Fortitude Biomedicines
- ·The full record, as it builds
Funding rounds
No funding rounds for Fortitude Biomedicines are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fortitude Biomedicines
Developer of biologic therapies designed for therapeutic discovery and advancement. The company integrates proprietary discovery approaches, biologic engineering capabilities, and targeted therapeutic design technologies that support the identification, optimization, and preclinical development of novel candidates, incorporating precision targeting concepts, molecular optimization processes, and translational research workflows, enabling biotechnology and pharmaceutical stakeholders to advance potential treatments for complex immune-mediated and oncologic conditions.
- Sector
- Healthcare
- HQ
- Waltham, MA, United States
- Founded
- 2025
- Employees
- 6
- Website
- fortitudebiomedicines.com/
- Ownership
- Privately Held (backing)
Fortitude Biomedicines doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fortitude Biomedicines shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fortitude Biomedicines in its N-PORT filings yet. We sweep new filings monthly.